The global ELISpot and FluoroSpot assays market had valuation of US $166 million in 2020 and is anticipated to be worth US $1.06 million by 2030 growing at a compound annual growth rate (CAGR) of 20.4% during the forecast period from 2021-2030.

The ELISpot and FluoroSpot assays methods are different ways a studying the immune system at a cellular level. In these methods, cells are cultured with antibodies on microscopic plates. Any molecular part released by cells are blocked by antibodies. This approach is used regularly used to study a variety of infectious disease and cancer research.

ELISpot is short for enzyme-linked immune absorbent spot is a technique to study the frequency of cytokines discharge from a single cell. Cytokines are a category of small proteins. ELISpot method is used to study innate and adaptive responses of the immune system. FluoroSpot technique uses properties of ELISpot method to study the secretion of more than one specimen at the same time. These methods help in assessing varied behavior and functions of cells who are at the same cellular level.

Factors Affecting

• The ELISpot and FluoroSpot methods are very efficient in studying behavior of pathogens which cause HIV, tuberculosis, hepatitis etc., which helps in vaccine development. This will result in increased demand of the global ELISpot and FluoroSpot assays market.
• ELISpot and FluoroSpot assays have many advantages for purposes like monitoring and treatment of viral infection, autoimmune disease and transplantation, vaccine development. This has caught the eyes of investors; many private and government institutions are funding researches which use these techniques. Due to this, the demand of global ELISpot and FluoroSpot assays market will increase.
• The popularity of ELISpot and FluoroSpot assays method is not enough to keep researchers on not relying on other methods. These methods can track only a small number of cell secretion, which highly increases the chances of cell loss during the process. This may slow down the growth of global ELISpot and FluoroSpot assays market.
• The availability of other options like Total Internal Reflection Fluoroscence Microscopy (TIRFM), micro engraving etc. may also decrease the demand of global ELISpot and FluoroSpot assays market.

Impact Analysis of Covid-19

The global ELISpot and FluoroSpot assays market experienced a rise in demand. This is due to Covid-19 overtook the expectations of many experts about the infection rate, and as it reached the status of pandemic. A requirement of virus study and how the human immune system can handle it was realized. This resulted in an upward demand for ELISpot and FluoroSpot assays from mainly vaccine developers and research organizations to conduct studies and tests for making vaccines as soon as possible. 

Regional Insights

In terms of region, North America is leading the global ELISpot and FluoroSpot assays market. This is due to increasing population of infected patients, well established medical infrastructure, presence of high number of industry players are the reasons for high demand in this region. North America is closely followed by Europe, due to rise of manufacturers and increasing application of sophisticated technology in the European medical infrastructure. 

Competitive Landscape

The most prominent players of global ELISpot and FluoroSpot assays market are:

• Abcam
• AutoimmunDiagnostika GmbH
• Becton, Dickinson and Company
• Bio-Connect B.V.
• Biotech Investissement Group
• Bio-Techne Corporation
• Cellular Technologies Limited
• Covance (LabCorp)
• Elabscience
• Lophius Biosciences GmbH
• Mabtech AB
• Oxford Immunotec
• Thermo Fisher Scientific
• U-Cytech Biosciences
• Other prominent players.

Scope of the Report

The global ELISpot and FluoroSpot assays market segment focus on Product, Application, End-User and Region

By Product

• Analyzers
• Assays Kits
• Ancillary Products

By Application

• Research Applications
• Clinical Trials
• Cancer Research
• Vaccine Development
• Diagnostics Applications
• Transplants
• Infectious Diseases

By End-User

• Hospitals and Clinics
• Bio-pharmaceuticals Companies
• Research Organizations

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• UAE
• Saudi Arabia
• South Africa
• Rest of MEA
• South America
• Brazil
• Argentina
• Rest of South America